A Phase 1 interventional study of Ontunisertib and [14C]ontunisertib in Fibrostenotic Crohn's Disease, sponsored by Agomab Spain S.L.U.. Recruiting at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Agomab Spain S.L.U. (part of Agomab Therapeutics NV) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 217 studies in Crohn Disease with a site in United Kingdom — 47 open to participants now, 66 under way, 26 of them phase 3. Crohn Disease · United Kingdom.
Among the 217 studies in Crohn Disease with a site in United Kingdom, this one is the 166th largest by planned enrollment of the 171 interventional ones that give a count, is one of 9 that started in 2026, is one of 10 in phase 1, reaches primary completion later than 16 of the 65 other live ones, and was the 214th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →47 of the 217 studies in Crohn Disease with a site in United Kingdom are open now. Recruiting first, the newest first:
Agomab Spain S.L.U. · Sites in United Kingdom, United States, Serbia
Ages 18+
Hoffmann-La Roche · Sites in United Kingdom, United States, Australia and 5 more countries
Ages 2–17
Takeda · Sites in United Kingdom
Ages 18–75
University of Nottingham · Sites in United Kingdom
Ages 16+
Janssen Research & Development, LLC · Sites in United Kingdom, United States, Argentina and 27 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 30 Years to 65 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
217 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 49 · Phase 3 75 · Phase 4 9
First in 2000; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 8 is below the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 168 across the 171 interventional studies, 245 across the 46 observational. Of the 135 that completed or were terminated, 75 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
137 of 217 have an industry lead sponsor. The 10 most frequent:
This study is registered under Agomab Spain S.L.U., one of the names counted as Agomab Therapeutics NV. Under that name alone:
Agomab Spain S.L.U. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Agomab Therapeutics NV has 4 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
14 of the studies in Crohn Disease with a site in United Kingdom that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
Add all 14 to your calendar (.ics) → With an account.
Among the 217 studies in Crohn Disease with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open, two-part study in healthy male volunteers, aged 30-65 years.
This trial aims to understand how the human body absorbs, distributes, metabolizes and eliminates ontunisertib after a single oral dose of radiolabelled test medicine ([14C]ontunisertib) and determine the routes and rates of elimination of the test medicine.
This is an open, two-part study in healthy male volunteers, aged 30-65 years with the trial duration of approximately 7 weeks.
In Part 1 of this study, healthy volunteers will be given a dose of test medicine orally followed by an intravenous injection of a very small dose of radiolabelled test medicine that contains a tiny amount of radioactivity (called carbon-14) so that the test medicine can be traced in the blood.
In Part 2, single doses of test medicine will be administered orally to find out how the body breaks down and gets rid of the test medicine. The test medicine will be 'radiolabelled' - it will contain a small amount of radioactivity (Carbon-14) - so that it can be traced in the body.
Participants will take part in both study parts and will remain resident in the clinic for up to 10 days after their final dose of Investigation Medicinal Product (IMP). After the participants have left the clinic, they may have to collect their urine and faeces at home until mass balance criteria has been met.
Over a period of at least 8 days in Part 1 and 10 days in Part 2, many blood samples will be taken, and volunteers will collect all their urine and faeces so that the amount of test medicine and its breakdown products can be measured/analysed.
A blood sample will be taken from volunteers between admission and first dose for pharmacogenetic testing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single oral dose of ontunisertib
Drug: Ontunisertib
Participants will receive single IV dose of \[14C\]ontunisertib
Drug: [14C]ontunisertib
Participants will receive single oral dose of \[14C\]ontunisertib
Drug: [14C]ontunisertib
Oral capsule
Also known as: AGMB-129
IV infusion
Oral capsule
Absolute bioavailability of ontunisertib following oral and IV administration
Part 1: To determine the absolute oral bioavailability of ontunisertib
Time frame: Through study completion, an average of 8 days
Cumulative amount of total radioactivity excreted in urine and feces
Part 2: To determine the mass balance recovery after a single oral dose of \[14C\]ontunisertib
Time frame: Through study completion, an average of 10 days
Chemical structure of each metabolite accounting for ≥10% of circulating total radioactivity and Metabolite profiling accounting for >80% of total radioactivity recovered in urine and/or feces
Part 2: To characterize the metabolite profile in plasma and excreta (urine and/or feces) after a single oral dose of \[14C\]ontunisertib
Time frame: Through study completion, an average of 10 days
PK parameter (AUClast)
Part 1: To characterize the IV PK (AUClast) of \[14C\]ontunisertib and total radioactivity in plasma
Time frame: Through study completion, an average of 8 days
Cumulative amount of total radioactivity excreted in urine and feces following IV administration
Part 1: To determine the mass balance recovery after a single IV dose of \[14C\]ontunisertib
Time frame: Through study completion, an average of 8 days
PK parameter (AUClast)
Part 1 and Part 2: To characterize the plasma PK (AUClast) of ontunisertib and metabolites and total radioactivity (Part 2 only) following a single oral dose
Time frame: Through study completion, an average of 18 days
Whole blood-to-plasma concentration ratios for total radioactivity
Part 2: To evaluate the extent of distribution of total radioactivity into blood cells
Time frame: Through study completion, an average of 10 days
Number of participants with adverse events (AEs)
Part 1 and Part 2: To assess the safety and tolerability of ontunisertib
Time frame: Through study completion, an average of 18 days
Number of participants with abnormal physical examinations
Part 1 and Part 2: To assess the safety and tolerability of ontunisertib
Time frame: Through study completion, an average of 18 days
Number of participants with abnormal vital signs
Part 1 and Part 2: To assess the safety and tolerability of ontunisertib
Time frame: Through study completion, an average of 18 days
Number of participants with abnormal ECGs parameters
Part 1 and Part 2: To assess the safety and tolerability of ontunisertib
Time frame: Through study completion, an average of 18 days
Number of participants with abnormal clinical laboratory safety tests
Part 1 and Part 2: To assess the safety and tolerability of ontunisertib
Time frame: Through study completion, an average of 18 days
Chemical structure analysis of metabolites accounting for ≥10%
Part 1: To characterize the metabolites profile in plasma following an IV dose of \[14C\]ontunisertib
Time frame: Through study completion, an average of 8 days
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Sep 2026, 0 months after the start.
Of 33 industry-sponsored phase 1 interventional studies under Crohn Disease, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 0 months is below that.
Counting every sponsor, half of 61 studies reached it within 22 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ontunisertib